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Isl1β  over-expression with key β  cell transcription factors 
enhances glucose-responsive, hepatic insulin production and secretion 
 
Yunshin Jung 
 
ABSTRACT 
Adenoviral gene transfer of key β cell developmental regulators including Pdx1, 
Neurod1 and Mafa (PDA) has been reported to generate insulin-producing cells in liver. 
However, PDA insulin secretion is transient and glucose unresponsive. Here, I report that 
an additional β cell developmental regulator, insulin gene enhancer binding protein 
splicing variant (Isl1β), improved insulin production and glucose-responsive insulin 
secretion in PDA mouse. Microarray gene expression analysis suggested that adenoviral 
PDA transfer required an additional element for mature β cell generation, such as Isl1 and 
Elf3 in liver. In vitro promoter analysis indicated that splicing variant Isl1, Isl1β is an 
important factor for transcriptional activity of insulin gene. In vivo bioluminescence 
monitoring using insulin promoter-luciferase transgenic (MIP-Luc-VU) mice verified that 
adenoviral PDA-Isl1β transfer produced highly intense luminescence from the liver which 
peaked at day 7 and persisted for more than 10 days. Using insulin promoter-GFP 
transgenic (MIP-GFP) mice, I further confirmed that Isl1β supplementation to PDA 
augmented insulin-producing cells in liver, insulin production and secretion, and β cell 
related genes. Finally, PDA-Isl1β combination ameliorated hyperglycemia in diabetic mice 
for 28 days and enhanced glucose tolerance and responsiveness. Thus, my results suggest 
that Isl1β is a key additional transcriptional factor for processing the generation of insulin 
producing cells in liver in combination with PDA. 
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Chapter 1:  General introduction 
 
1.1. Diabetes and β cell generation 
 
β cell replacement as diabetes treatment is a desirable therapeutic approach. One 
of the existing β cell sources is human cadaveric pancreatic islet, but lifetime 
immunosuppressive drug administration and organ scarcity demand alternative supply 
(1, 2). The ultimate solution is generation of insulin-producing β-like cells that mimic 
the insulin production and release function of endogenous pancreatic β cells. In vitro β 
cell generation from induced pluripotent stem cells or embryonic stem cells (iPSC or 
ESC) (3, 4), although very progressive, has potentially limited clinical application as: 
1) The existing genetic diabetic predisposition could affect the cell pluripotency (5, 6); 
2) The reprogramming process and subsequent expansion of iPSCs can cause genetic 
and epigenetic abnormalities, possibly triggering autologous immune response (7, 8); 
3) It requires time and money consuming multi-step procedures to produce and 
maintain sufficient amount of β cell mass and to transplant (9). 
 
1.2. In vivo β cell generation through direct reprogramming 
 
An alternative strategy is in vivo direct reprogramming into β-like cell from 
extrapancreatic tissues including liver by force-expressing insulin-activating key β cell 
developmental transcription factors such as pancreatic and duodenal homeobox gene 1 
(Pdx1), basic helix-loop-helix transcription factor (Neurod1) and MAF basic leucine 
zipper (Mafa) (10–13).  Pdx1, a key pancreatic developmental regulator, was reported 
for the ability of hepatic insulin production transiently, but not of glucose response 
(10). Neurod1, an endocrine specification regulator, showed higher efficacy in liver 
insulin production than Pdx1, but glucose stimulated insulin secretion was negligible, 
even under longer expression (11). Addition of β cell specific maturation marker, 
Mafa, to Pdx1 and Neurod1, demonstrated greatly increased hepatic insulin 
production capacity and yet, transient and glucose-unresponsive insulin secretion was 
not improved (12,13). Taken together, previous studies suggest that this three-gene 
combination (PDA) was not sufficient to prolong insulin production nor to generate 
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glucose-responsive β-like cells (10–13) from liver, and thereby requires additional 
transcription factor. 
 
1.3. Function of Isl1 in pancreas 
 
Insulin enhancer binding protein-1 (ISL-1), a member of LIM-homeodomain 
family, is a well-known activator of insulin gene (14,15) and essential for the 
development of pancreas (16). It also plays a crucial role in proliferation, maturation 
and functional maintenance of pancreatic islet cells including β cell (17–20). Isl1-
deficient mice in β cell had shown to fail functional maturation of β cell and 
consequently developed diabetes (17,19). In particular, Isl1 was reported to physically 
interact with NeuroD to synergistically activate insulin transcription (21,22)and to 
directly regulate the gene transcription of Mafa (17) and Pdx1 (19). This supports the 
approach of Isl1 as a key extrapancreatic insulin producing factor, which was first 
introduced by Kojima et al.’s study from immature rat intestinal stem cell (IEC-6) 
(23). Single overexpression of Pdx1 in IEC-6 failed to generate insulin producing 
cells, which was resolved by additional treatment of Isl1 but without functional 
maturation (23). However, the role of Isl1 in generating β cell through directly 
converting mouse liver has not been investigated yet. 
 
1.4. Overview and Objectives 
 
In this study, I report a comparative gene-expression analysis of PDA-driven 
liver insulin-producing cells for the first time, in order to discover additional element, 
i.e. Isl1β, Isl1 splicing variant. I then demonstrate that the adenoviral expression of 
Isl1β, in combination to PDA in mouse liver improved insulin production and glucose-
responsive insulin secretion. 
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Chapter 2:  Materials and Methods 
 
1.1. Animals 
 
All experiments were conducted according to the relevant Japanese and 
institutional law and guidelines and authorized by the University of Tsukuba animal 
ethics committee (authorization number 13-072). The purchase and maintenance of 
transgenic mice MIP-Luc-VU [FVB/N-Tg(ins-luc)-VUPwrs/J, #JAX:007800] were 
described previously (13,24). MIP-GFP transgenic mice expressing green fluorescent 
protein under mouse insulin 1 promoter were kindly gifted from Dr. Manami Hara 
(The University of Chicago, USA) and maintained by breeding with Jcl:ICR mice 
(Clea Japan, Tokyo, Japan) (13). Mice were euthanized at the appropriate time points 
with carbon dioxide gas. 
 
1.2. Adenovirus production and injection 
 
Recombinant adenoviruses expressing GFP (Ad-GFP), LacZ (Ad-LacZ), polycistronic 
mouse Pdx1, Nuerod1 and Mafa (Ad-PDA) and mouse Isl1β (Ad-Isl1β) were 
generated using the ViraPower Adenoviral Gateway Expression kit (Life 
Technologies) as previously described (13). Polycistronic PDA is linked through P2A 
and T2A as follows: Pdx1-P2A-Neurod1-T2A-Mafa. Isl1α, Isl1β and Elf3 were 
cloned from MIN6 cDNA. Isl1β was confirmed by negative PCR amplification from 
69 missing base pair sequences in splicing variant. Virus propagation, purification and 
titer determination were carried out following previously published methods (13). The 
efficacious adenoviral gene transfer delineates the virus titer of 2.5x109 infectious 
units. Adenovirus was injected into 7-8 weeks old mice through tail vein at free fed 
status. 
 
1.3. Fluorescence-activated cell sorting (FACS) of GFP expressing liver cells 
 
At day 7 of adenoviral injection into MIP-GFP mice (25), liver perfusion was 
conducted under anesthesia. 37°C pre-warmed 0.5 mM EGTA-Hanks buffer (Gibco) 
was perfused through hepatic portal vein, followed by 1 mg/ml collagenase II 
(Gibco) containing 5 mM CaCl2-Hanks buffer. Liver was dissected and chopped into 
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small pieces by scissors, washed with cold Hanks buffer and filtered through 70 µm 
cell strainer (BD Bioscience). Collected liver cells were centrifuged at 1000 rpm for 
1 minute; supernatant was discarded to remove blood cells. Cell pellets were washed 
with cold Hanks buffer twice. At final washing, cell pellets were re-suspended with 
2% FBS, 2 mM EDTA, DMEM (all Gibco) and subjected to FACS (MofloXdp, 
Beckman) by GFP expression. 
 
1.4. Microarray analysis, Promoter analysis, Pathway analysis 
 
Total RNA was extracted from three MIP-GFP mice and pooled by equal 
RNA concentrations to synthesize a single cDNA sample from each mouse. Liver 
and pancreatic islets pooled from 3 mice, without adenoviral infection were used as 
negative and positive control, respectively. Pancreatic islets were isolated by the 
standard collagenase digestion protocol using Collagenase type V (Wako), and then 
hand-picked (26). NucleoSpin RNA kit (Macherey-Nagel) was used to isolate RNA 
from collected tissues. First-cycle cDNA, cRNA and second-cycle cDNA were 
synthesized according to the protocol of the Ambion WT Expression Kit (Life 
Technologies). cDNA was fragmented and labeled using the GeneChip WT 
Terminal Labeling and Control Kit (Affymetrix) and hybridized to the GeneChip 
MoGene-1_0-st-v1 cassettes array (Affymetrix), at 45°C for 17 hours. The 
GeneChip arrays were scanned using the GeneChip Scanner 3000 (Affymetrix). 
Image files were created using the GeneChip Command Console (Affymetrix); data 
were normalized using the Affymetrix Expression Console software. Gene 
expression values were compared by 2-fold cut-off [Fig. 3(a,b)]. Then gene ID was 
converted using an open web-base tool, Galaxy (#SCR006281) (27) and gene 
annotation was obtained from UCSI genome browser (28,29). Promoter region of 
300 bp upstream was analyzed by the online motif-based sequence analysis tool, the 
MEME Suite (Motif-based sequence analysis tools, #SCR001783) from “DREME 
and TOMTOM” (30,31). Pathway analysis was performed through an open-source 
software DAVID (#SCR001881) using the database of Kyoto Encyclopedia of 
Genes and Genomes (KEGG, #SCR012773) (32,33). 
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1.5. Heat map and Microarray based filtering algorithm 
 
Using the sane microarray data set in Figure 2, heatmap was created using an 
open-source application of microarray software suite, multiexperiment viewer (Tm4: 
MeV, #SCR001915) [Fig. 2(b)] (34). Venn diagram of microarray scatter plot was 
created by a free web application, (GeneVenn, #SCR012117) [Fig. 3(c)] (35). Tissue 
differential expression was verified using an online software tool, Beta Cell Gene 
Atlas database (T1DBase, #SCR007959) [Fig. 3(d)] (36). 
 
1.6. Plasmid construct and Luciferase assay 
 
Previously constructed pGL2/RIPII-251 plasmid was used for luciferase assay 
[Fig. 3(g)] (37). Adenoviral vectors pAd-PDA, pAd-Isl1α, pAd-Isl1β and pAd-Elf3 
were co-transfected with pGL2 constructs in 293A cell for 24 hours using 
polyethylenimine (PEI, Polysciences). Luciferase activities were normalized to 
Renilla luciferase activity according to the Dual Luciferase Reporter Assay System 
(Promega). 
 
1.7. Western blot 
 
293A cells transfected for 24 hours in luciferase assay were lysed with 20 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% 
sodium deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM β-glycerophosphate, 1 
mM Na3VO4, 1 µg/ml leupeptin and complete protease inhibitor cocktail (Roche). 
Protein concentrations were measured with coomassie protein assay reagent (Thermo 
Scientific). 20 µg of protein extracts were run on 10% SDS-polyacrylamide gels, 
followed by electrophoretic transfer to a polyvinylidene difluoride (pvdf) membrane 
(Merck Millipore). After 1 hour blocking at room temperature with 5% skim milk 
(Wako), immunoblots were incubated at 4°C in primary antibodies overnight against 
Pdx1 (Abcam, #AB777178), NeuroD (Santa Cruz, #AB2282474), MafA (Bethyl 
Laboratories, #AB1279486), Isl1 (DSHB, #AB528315), Elf3 (R&D systems, 
#AB2278132) and β-actin (MBL, #AB10697035). Blots were then incubated with 
secondary antibodies for 1 hour at room temperature and proteins were detected 
using chemiluminescence HRP substrate (Millipore). 
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1.8. Bioluminescence imaging 
 
At day 0, adenoviruses (Ad-GFP, Ad-PDA, and Ad-Isl1β) were transferred into 
the MIP-Luc-VU mice (13,24). The bioluminescence signals were detected after 5 
minutes of D-luciferin injection (Promega) intraperitoneally with the dosage of 5 
mg/kg body weight using an IVIS spectrum (Caliper Life Sciences). 
Bioluminescence images were obtained within 1 minute integration time. Isometric 
regions of interest (ROIs) were automatically captured to quantify the signals 
emitted from the liver by Living Image software (Xenogen Corporation). 
 
1.9. Immunohistochemistry 
 
At 1 week of adenoviral treatment, livers from MIP-GFP mice were collected. 
Tissue was fixed in 4% PFA on ice for 4 hours, followed by 30% sucrose PBS 
solution, overnight at 4°C. Fixed liver was embedded in O.C.T compound (Tissue-
Tek), frozen and sliced by 5 µm thickness using a cryostat (Leica). Primary 
antibodies were applied to the sections: anti-Insulin antibody (Abcam, #AB306130), 
anti-Glucagon (Takara, #AB2619627), anti-Pdx1 (Abcam, #AB777178), anti-
NeuroD (Santa Cruz, #AB2282474), anti-MafA (Bethyl Laboratories, #AB1279486) 
and anti-Isl1 (D41SHB, #AB528315) overnight at 4°C. Secondary antibody 
conjugated with Alexa 594 or 633 (Life Technology,  #AB2534120 or #AB2535739) 
was incubated with nuclear staining using DAPI (Invitrogen, #AB2307445) at room 
temperature for 1 hour. Section images were obtained using Biorevo BZ-9000 
microscope (Keyence) and BZ-II Analyzer software (Keyence). 
 
1.10. Total liver RNA extraction, cDNA synthesis and quantitative Real-time 
RT-PCR 
 
Total liver RNA was extracted by using standard Trizol RNA extraction 
method (ISOGEN). 1 µg of cDNA was synthesized following the protocol of 
QuantiTect Reverse Transcription kit (Qiagen). Real-time RT-PCR was performed 
with SYBR Green PCR master mix (Takara) using the Thermal Cycler Dice Real 
Time system (Takara) to detect gene expression level, and normalized to Hprt. All 
primer sequences are listed in Table 1. 
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1.11. Measurement of insulin content 
 
Hepatic insulin contents at 7 days of adenovirus treatment and pancreatic 
insulin contents at 28 days of STZ induction were extracted using the standard acid-
ethanol method as previously described (13,38). Then insulin contents were 
measured by an insulin enzyme-linked immunesorbent assay kit (Morinaga). Total 
protein concentration was calculated using coomassie protein assay reagent (Thermo 
Scientific) to normalize insulin contents. 
 
1.12. Fed blood glucose and body weight measurement 
 
MIP-GFP mice were treated with either Ad-PDA+LacZ or Ad-PDA+Isl1β and 
analyzed blood glucose after 1 week of adenoviral treatment at free fed status. Fed 
blood glucose was measured in the late morning after 1 hour of fasting from tail 
snip. Before 1 hour fasting in the morning, body weight of the animal was measured 
at day 0, 3 and 7 of adenoviral treatment. 
 
1.13. Diabetes induction 
 
A single injection of streptozotocin (STZ) (Wako) was intraperitoneally 
administered to 5 weeks old wild-type mice (ICR) to induce diabetes at a dosage of 
200 mg/kg body weight dissolved in 0.1 M citrate buffer (pH 4.5). Plasma glucose 
level was measured with one-touch blood glucometer (Medi-safe-reader, Terumo). 
After 5 days of STZ induction, hyperglycemic mice are selected by examining 
fasting blood glucose ( > 200 mg/dl) and fed blood glucose ( > 400 mg/dl). Fasting 
blood glucose concentration was measured after 16 hours of fasting; fed blood 
glucose was measured in the late morning after 1 hour of fasting. 
 
1.14. Glucose and Hormone Assays 
 
After 1 week of STZ induction, diabetic animals were administered with one 
third of standard adenovirus titer. At day 7 of adenoviral treatment, mice were 
challenged with glucose intraperitoneally after overnight fasting (16 hours) at a 
dosage of 2 g/kg body weight and measured plasma glucose levels at 0, 15 and 30 
minutes and every 30 minutes for 2 hours. Serum insulin was collected at 0 and 30 
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minutes and measured using an ultrasensitive insulin enzyme-linked immunesorbent 
assay kit (Morinaga). 
 
1.15. Statistical analyses 
 
All data values are presented as means ± s.e.m. of minimum three independent 
experiments. Probability values were calculated by using unpaired Student’s t-test or 
two-way ANOVA followed by Tukey’s Honest Significant Difference for multiple 
comparison analysis, unless otherwise mentioned. P-values less than 0.05 were 
considered significant. 
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Chapter 3:  Results 
 
1.1. Microarray analysis of PDA driven insulin-producing cells in liver 
 
In order to analyze the defects of insulin-producing liver cells generated by three 
key trasncription factors including Pdx1, Neurod1 and Mafa (PDA) at gene level, I 
injected PDA recombinant adenovirus (Ad-PDA) into transgenic mice which express 
green fluorescent protein under the control of mouse insulin 1 promoter (MIP-GFP) 
(25). Based on previous results that PDA gene expression persists after 7 days of 
infection (13), I  isolated GFP expressing cells in liver, extracted RNA and 
synthesized cDNA from three mice at day 7 of PDA injection [Fig. 1(a)]. After 
confirming successful PDA gene induction in mouse liver [Fig. 1(b-d)], I compared 
the expression levels of Ins1 and Ins2 in PDA expressing liver cells (PDA-cell) and 
pancreatic islet. This data revealed approximately 50-fold differences [Fig. 2(a)] and 
thus indicate that adenoviral overexpression of PDA in liver is insufficient to activate 
comparable insulin transcription to mature β cells. 
To examine differential gene expression patterns between PDA-cell and 
pancreatic islet, I conducted microarray gene expression analysis (34) [Fig. 2(b)]. 
Importantly, PDA-cell did not upregulate most of β cell hallmark genes (4) including 
Nkx2.2, Pax6, Isl1, Ucn3 and probably endogenous Pdx1 [Fig. 2(b)]. I then designed 
special primers that exclusively detect endogenous expression of Pdx1, Neurod1 and 
Mafa from amplifying 3’ UTR region [Fig. 2(c)]. qRT-PCR analysis using the 
endogenous primers further verified that the expression levels of β cell hallmark genes 
were negligible [Fig. 2(d)], consistent with microarray results. These data suggest that 
PDA-cell requires other regulators to improve insulin production and/or glucose 
responsiveness. 
 
1.2. Screening of additional factor(s) by microarray-based algorithm 
 
In searching for the additional factor for PDA-cell, I devised a filtering 
algorithm to select islet-enriched genes that were not upregulated in PDA-cell. Firstly, 
two microarray gene scatterplots showed unique islet-enriched gene profiles in each 
group [Fig. 3(a,b)]. I obtained 2478 genes by interesting those two different islet-
enriched gene sets (A and B from Figure 3(a) and 3(b), respectively), using an open 
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web application software, GeneVenn (35) to remove background effect caused by 
adenovirus delivery [Fig. 3(c)]. Next, 87 genes were acquired from overlap of explicit 
gene expressions in both pancreas and pancreatic islet cells to eliminate genes 
expressed in pancreatic exocrine tissue but not in islet [Fig. 3(d)]. Tissue expression 
pattern was then evaluated, which marked 24 genes as pancreatic islet specific, using 
an open-source software, Beta Cell Atlas (36) [Fig. 3(d)]. These candidate genes were 
highly expressed in pancreatic islet but undetectable in both hepatocyte and PDA-cell 
[Fig. 3(e)], further confirmed by qRT-PCR analysis [Fig. 3(f)]. Finally, I selected two 
transcription factors: Isl1 and Elf3. Because it was reported that splicing variant Isl1 
(Isl1β) is more potent insulin activator than canonical Isl1 (Isl1α) and confined to β 
cell lines (39,40), I decided to examine Isl1β, too. To verify the effects of those 
transcription factors on insulin expression, I performed in vitro insulin promoter assay 
using rat insulin promoter II (37), as major regulatory elements are mostly shared 
between rat insulin promoter II and mouse insulin I promoter [Fig. 3(g)]. Promoter 
assay clearly showed that Isl1β had the most additive effect on insulin promoter 
activity [Fig. 3(h)]. Given that expression levels of transfected genes were all similar 
by western blot [Fig. 3(h)], these data suggest that Isl1β is one of the important 
transcriptional factors to increase insulin promoter activity in combination with PDA. 
 
1.3. In vivo validation of additional factor, Isl1β, using MIP-Luc-VU 
 
To examine the transcriptional activity of the intrahepatic insulin gene in a 
noninvasive manner, I monitored the bioluminescence emissions from transgenic mice 
(MIP-Luc-VU) expressing luciferase under the control of the mouse insulin 1 
promoter (24), after adenoviral treatment. I injected adenoviral Isl1β (Ad-Isl1β) into 
MIP-Luc-VU mice at 8 weeks old age with combination of adenoviral PDA (Ad-
PDA). I monitored insulin transcriptional dynamics after luciferin injection (5 mg/kg 
body weight, IP) into Ad-PDA+Isl1β mouse for two times per week by detecting 
hepatic signals, emitted from the upper abdomen of the animal [Fig. 4(a)]. 
Transcriptional activity of hepatic insulin promoter of Ad-PDA+GFP peaked at day 3 
and gradually disappeared at day 7 from the liver [Fig. 4(b,c)]. In contrast, hepatic 
insulin transcriptional peak of Ad-PDA +Isl1β was shifted to day 7 and transcriptional 
activity lasted over 10 days in the liver, indicating that Ad-PDA+Isl1β treatment 
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prolonged insulin production through increasing insulin promoter activity about 2-fold 
compared to control [Fig. 4(c)]. These in vivo results further support that Isl1β is one 
of the additional key transcriptional factors for insulin production and extension in 
combination with PDA. 
 
1.4. In vivo validation of Ad-PDA+Isl1β using MIP-GFP 
 
1-4-1. Isl1β addition enhanced insulin production and secretion in MIP-GFP mice. 
 
To further explore additive effects of Isl1β in vivo, I injected adenoviral 
PDA+Isl1β and PDA+LacZ into MIP-GFP mice (25) at 8 weeks old age. To first 
confirm the adenoviral gene transfer in liver at day 7, I performed immunofluorescent 
analysis with each antibody including Isl1β, Pdx1, NeuroD, MafA, Insulin and 
Glucagon. The results showed that all genes were successfully expressed in liver [Fig. 
5(a-c)], and GFP expressing cells were frequently overlapped with Pdx1, NeuroD, 
MafA [Fig. 5(a-c)] and Insulin signals [Fig. 5(d)] but not with Glucagon [Fig. 5(e)]. 
Notably, Isl1β signal was well correlated with GFP expressing cells, indicating that 
Isl1β is important for hepatic insulin production [Fig. 4(a)]. 
I then compared PDA, Isl1β and Ins1/2 levels by qRT-PCR analysis from day 7 
of whole liver RNA, but interestingly, both Insulin and PDA levels were increased by 
the addition of Isl1β [Fig. 6(a,b)], when the same virus titer of Ad-PDA was delivered 
to each group. Thus, I first assumed that Isl1β addition would augment hepatic insulin 
transcriptional activity by increasing GFP expressing cell number and/or GFP 
intensity. To test this possibility, I quantified GFP expressing cells by FACS after 
collagenase liver perfusion and GFP expressing cells by Ad-PDA+Isl1β treatment 
were increased more than 10-fold compared to control [Fig. 6(c)]. Moreover, qRT-
PCR analysis of isolated GFP expressing cells showed that Isl1β expression 
significantly increased the expression levels of Ins1 and Ins2, suggesting that Isl1β 
contributes to both qualitative and quantitative hepatic insulin production [Fig. 6(d)]. 
To further evaluate insulin production and secretion properties in mice treated 
with adenovirus, I measured the contents of both hepatic and plasma insulin. Hepatic 
insulin contents of Ad-PDA+Isl1β were 1.7-fold higher compared to Ad-PDA+LacZ 
[Fig. 6(e)]; plasma insulin level was 1.9-fold higher in Ad-PDA+Isl1β mice [Fig. 6(f)]. 
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Consequently, blood glucose level was lower in Ad-PDA+Isl1β mice, but none of the 
mice fell into hypoglycemic shock nor exhibited abnormal eating behavior as 
indicated by insignificant body weight differences [Fig. 6(g,h)].  Taken together, those 
significantly higher levels of hepatic and plasma insulin suggest that the ectopic 
expression of Isl1β resulted in increased amount of insulin synthesis, processing and 
secretion in combination with PDA. 
 
1-4-2. Overexpression of Isl1β activates key β cell gene expressions. 
To assess gene expression changes of key β cell and hepatocyte markers in the 
liver of Ad-PDA+Isl1β, I performed qRT-PCR analysis using total RNA from mouse 
whole liver.  Because, Ad-PDA+Isl1β treatment resulted in an increase of Pdx1 and 
Neurod1 compared to Ad-PDA+LacZ [Fig. 6(a)], I assumed that Isl1β might activate 
endogenous expression levels of intrahepatic Pdx1 and Neurod1 as previously 
reported (41). To address this assumption, I again used specifically designed 
endogenous primers [Fig. 2(c)] for β cell specific genes, such as Pdx1, Neurod1, 
Mafa, Pax6, and Ucn3, and an α cell specific marker, Gcg [Fig. 7(a)]. The results 
confirmed that overexpression of Isl1β upregulated hepatic endogenous genes of 
Pdx1, Neurod1 and Pax6 but not endogenous Mafa and Gcg significantly, which 
could be explained by less abundant Isl1 co-factors in liver, required for potent Mafa 
activation (20,42,43). Moreover, Ad-PDA+Isl1β treatment markedly increased the 
mRNA levels of β cell functional genes involved in glucose stimulated insulin 
secretion such as Kir6.2, Pc2, Sur1 and Glut2 [Fig. 7(b)]. Unexpectedly, Isl1β 
addition also increased hepatocyte markers including Alb, Afp, and Hnf4α, although 
Alb and Hnf4α levels remained lower than the control liver [Fig. 7(c)]. This result 
suggests that Isl1β additional treatment does not contribute to liver dedifferentiation at 
day 7. Taken together, these data indicate that Isl1β assists to obtain several key β cell 
markers and functional genes, but not to inhibit liver markers, thereby suggesting a 
partial effect. 
1.5. Application of Ad-PDA+Isl1β in diabetic mice 
 
To determine whether hepatic insulin production induced by Ad-PDA+Isl1β 
treatment can ameliorate blood glucose level in diabetic mice, I injected 200 mg/kg 
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streptozotocin (STZ) into ICR mice, which caused hyperglycemia (higher than 200 
mg/dl glucose) after 4 days.  I treated mice systemically, 7 days after STZ injection, 
with Ad-PDA+LacZ, or Ad-PDA-Isl1β adenovirus and monitored fasting blood 
glucose concentrations for 28 days. Mice treated with Ad-PDA+LacZ initially 
maintained normal fasting blood glucose levels for one week but progressively 
increased fasting blood glucose levels [Fig. 8(a)]. In contrast, mice treated with Ad-
PDA+Isl1β showed a remarkable decrease in blood glucose levels from 400 mg/dl to 
below 100mg/dl after adenoviral treatments and maintained blood glucose levels 
below 200 mg/dl for two weeks, which remained at approximately 200 mg/dl for one 
month  [Fig. 8(a)]. Blood glucose area under the curve (AUC) clearly showed that Ad-
PDA+Isl1β treatment ameliorated blood glucose levels more efficiently compared to 
Ad-PDA+LacZ group [Fig. 8(b)]. At 28 days, I confirmed complete β-cell ablation by 
demonstrating negligible pancreatic insulin contents from adenoviral treated diabetic 
mice [Fig. 8(c)], which eliminates residual β cell effects. Because Ad-PDA+Isl1β 
treatment induced more mature and biologically active hepatic insulin production and 
secretion, I conclude that hepatic insulin production induced by Ad-PDA+Isl1β 
decreased blood glucose levels in STZ-induced diabetic mice. 
To assess the contribution of Ad-PDA+Isl1β treatments to glucose homeostasis, 
I performed intraperitoneal glucose tolerance test (IP-GTT, 2 g glucose/kg) after 7 
days of adenoviral treatments in STZ-induced diabetic mice [Fig. 8(d)]. Compared to 
Ad-PDA+LacZ mice, mice treated with Ad-PDA+Isl1β had a marked improvement in 
glucose clearance after glucose injection [Fig. 8(d)], as it was illustrated by area under 
the curve [Fig. 8(e)]. 
To further characterize glucose-stimulated hepatic insulin production and 
secretion in mice treated with Ad-PDA+LacZ or Ad-PDA+Isl1β in STZ-induced 
diabetic mice, I measured fasting and glucose-stimulated hepatic insulin. I found that 
the levels of hepatic insulin in mice treated with Ad-PDA+Isl1β were 1.7- and 2.7-
fold higher in both fasting and glucose-stimulated status than Ad-PDA+LacZ group 
[Fig. 8(f)]. Furthermore, mice treated with Ad-PDA+Isl1β secreted 1.6-fold more 
insulin following glucose stimulation [Fig. 8(f)], suggesting that Isl1β expression 
increases the capacity and glucose responsiveness of hepatic insulin-producing cells to 
release insulin following glucose stimulation. 
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Chapter 4:  Discussion 
 
In this study, I demonstrated that an additional insulin-producing factor, Isl1β, in 
combination with PDA extended the overall duration of hepatic insulin transcriptional 
activity by increasing both insulin transcriptional activity and insulin producing cell 
numbers. Furthermore, Ad-PDA+Isl1β treatment activated several β cell associated genes, 
and consequently ameliorated hyperglycemia and improved glucose sensitive inulin 
production and secretion in diabetic mouse. Therefore, I propose that Isl1β is required for 
generation of glucose responsive insulin producing cells in liver combined with PDA.  
 
Splicing variant Isl1β was first reported from MIN6 β cell line as lacking one of 
the Lhx-3 binding domain (LBD1, 23 amino acids) near C-terminus (39). LBD of Isl1 is 
required to bind to LIM homeobox protein 3 (Lhx3), through which their transcriptional 
activity is increased (39,40,44). Thus, Isl1β abolishes the synergistic transcriptional 
activity of Isl1/Lhx3 complex due to poor interaction with Lhx3 (39,40,44). However, 
Isl1/Lhx3 protein interaction occurs predominantly in neuronal tissues for driving neuro-
differentiation, and is rarely found in pancreatic islet (39,40,44). Moreover, insulin 
transcriptional co-activators of Isl1 such as NeuroD (21,22) and Hnf4α (45) do not require 
LBD for functional binding, thereby presumably maintaining the same function with Isl1β. 
Interestingly, LBD is also described for transcriptional repressive role by folding Isl1 
protein, which eventually hinders protein interactions with its co-factors (44). Therefore, 
Isl1β is assumed to form less self-protein folding, and become more accessible to its 
binding partners, which in turn increases its transcriptional activity on target genes, 
allegedly insulin (39,44). Nevertheless, the same biological validity of Isl1β as Isl1 could 
not be determined in pancreatic islet, as Isl1β is exclusively expressed in β cell lines, 
whereas Isl1 is expressed in both α and β cell (39). Furthermore, whether hepatic NeuroD 
and Hnf4α in our study interacted with Isl1β is not directly addressed; interacting binding 
domains of Isl1 co-factors, Ldb1 (20,42) and SSBP3 (43) in islet, have not been 
elucidated; and if Isl1 is less potent than Isl1β in activating its target genes  such as Ins, 
Mafa and Gcg in liver is not identified. Because Isl1β remains largely elusive, future 
studies of Isl1β function in pancreatic islet are required to illuminate more precise roles of 
Isl1β in β cell generation.  
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The extension of hepatic insulin transcriptional activities [Fig. 4] and improved 
glucose responsiveness [Fig. 8(f)] could be attributed to changes in endogenous gene 
expression of liver, given that adenoviral sustainability was unaffected by Isl1β addition. 
Evidently, many of β cell signature genes including Pdx1 and Neurod1 were endogenously 
induced in Ad-PDA+Isl1β treated liver [Fig. 7(a,b)], whereas PDA-cell mostly relied on 
ectopic gene expression [Fig. 2(b,d)]. Since NeuroD can interact with either Pdx1 (46,47) 
or Isl1 (21,22)  on insulin promoter, more hepatic Pdx1 and NeuroD proteins would form 
abundant complexes of NeuroD/Pdx1 and NeuroD/Isl1β, at PDA+Isl1β liver. 
Consequently, the number of insulin producing cells and the total insulin transcriptional 
activity were increased [Fig. 6(c,d)], emitting the peak signal at day 7. However, in the 
absence of Isl1β, limited number of NeuroD/Pdx1 complex was formed, producing the 
peak at day 3, which gradually faded at day 7 without additional Pdx1 and NeuroD 
proteins. Similarly, PDA+Isl1β and increased β cell functional genes [Fig. 7(b)] probably 
improved the glucose responsiveness [Fig. 8(f)], as NeuroD can also contribute to 
regulation of insulin transcription depending on different glucose concentrations through 
changing its binding partners, from Isl1 at low glucose level to Pdx1 at high (46). 
Strikingly, previous β cell reprogramming works in liver by overexpressing either a single 
Ngn3 (Neurogenin-3, an endocrine progenitor marker) (48), or a combination of Pdx1, 
Ngn3 and Mafa (PNM) (49) demonstrated that these hepatic neo-β cells were functional 
and exhibited drastically increased Isl1 level (48,49). Although, benefits of stable ectopic 
expression from using immunodeficient mice (49), or adeno-associated virus (48) could 
not be ignored, this could imply some degree of Isl1 contribution to functional β cell 
generation in liver. However, the additional effects of Isl1β do not continue after 14 days, 
probably due to a prompt immune-mediated adenovirus clearance [Fig. 1(d)]. Therefore, 
further study of stable PDA+Isl1β system will elucidate whether functional hepatic insulin 
producing cells could be maintained or not.  
Uninhibited liver markers [Fig. 7(c)] were often reported in both direct (50) and 
step-wise (46) β cell reprogramming field. Yang et al.’s PNM directed reprograming in 
liver demonstrated that Afp level was continuously higher and Alb started to decrease 
lower than the control at 56 days of gene delivery (50). The inhibition of Alb was 
explained by maturing reprogrammed insulin producing cells, as glucose tolerance was 
first detected at day 56 (50). Similarly, β cell differentiation of murine embryonic stem 
cells in culture exhibited a gradual and significant increase of Alb and Hnf4α in parallel to 
 20 
Ins1/2 levels, which was also interpreted as immaturity (51). In contrast, steadily 
converted, functional, hepatic neo-β cells did not express Alb, and persevered β-like cell 
phenotype (48,49). From this, our addition of Isl1β can be said to initiate β cell 
conversion, but stopped before reaching the maturation process, thus a partial conversion. 
Because, successful liver reprogramming was reported only from stable overexpression 
condition (48,49), our partial conversion could be resulted from transient expression 
system. Given that spontaneous Alb inhibition necessitated 12 weeks (48,49), whether 
persistent expression of PDA+Isl1β eventually inhibits liver markers and promotes the 
beneficial effects would be of interest for future studies.  
 
Another pancreatic endoderm tissues, exocrine (52,53) and α cells (54,55,56) are 
also favored for β cell reprogramming. Zhou et al.’ group (52) first demonstrated the most 
efficient β-cell reprogramming factor combinations, PNM, in exocrine tissue through 
adenoviral administration in immunodeficient mice (52). PNM overexpressing acinar cells 
lost amylase expression (52,53), exhibited glucose responsiveness, and importantly 
maintained the converted features (53). In contrast, α cells, known for high plastic 
epigenomic state, can be converted into β cells by lower degree of gene manipulation (54), 
such as 1) histone modification in vitro (54), or in vivo single gene modification of either 
2) Pax4 overexpression (55) or 3) Arx inhibition (56) in α cell. Although, modification of 
methylation pattern could not avoid glucagon coexpression in cultured islets (54), α cells 
from both genetically modified mice were successfully reprogrammed to functional β cells 
and maintained their newly adopted features, under glucagon supplementation (55,56). 
Nevertheless, specifically targeting α cells (54) or exocrine cells (52,53) is technically 
challenging due to deep anatomical location of pancreas; and tissue specific conditional 
knock-out (56) or knock-in strategy (55) is not clinically actionable. Of note, liver was 
effective to generate functional β cell through adenovirus mediated gene transfer both 
permanently, as mentioned above, (48,49) and transiently i.e. our Ad-PDA+Isl1β 
treatment. Moreover, commonly shared pancreatic progenitor Sox9 (49), large capacity 
and high proliferating rate of liver gives high tissue compatibility and targetability under 
intravenous injection of ectopic genes, bearing minimum invasiveness. Therefore, liver 
can be the most relevant extrapancreatic insulin producing tissue to future clinical 
application.  
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 Lastly, Elf3 (a E74 like ETS transcription factor 3), exhibited an unexpectedly 
extensive inhibition on insulin transcriptional activity, by repressing PDA protein levels 
[Fig. 3(g)] but not transcriptional levels [Fig. 3(i)]. This would certainly shed light on to a 
new inhibitory mechanism of insulin production. This further raises the possibility of 
multiple functionality of non-transcriptional remaining 22 candidates [Fig. 3(e)] on insulin 
production, including one identified islet cells autoantigen of type I diabetes, Ptprn 
(protein tyrosine phosphatase receptor type N) (57). Future in vivo screening analysis will 
be essential to follow up on these candidates. 
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Chapter 5:  Figures and Legends 
 
1.1. Confirmation of PDA adenoviral gene induction in PDA-cell. 
       
 
Figure 1. (a) A schematic diagram of isolation of PDA-cell. At day 7 of Ad-PDA 
injection into MIP-GFP mouse, liver cells were analyzed by flow cytometry and 
purified by GFP expression level. At day 7 of PDA injection into MIP-GFP mouse, 
liver cells were purified by positive GFP expression using FACS, extracted RNA and 
synthesized cDNA. RNAs from 3 individual mice were combined together to 
synthesize one cDNA. Expression values were normalized to Hprt. (b) mRNA level of 
Pdx1, Neurod1 and Mafa by qRT-PCR using CDS primers [Fig.2(c)]. (c) Promoter 
analysis of highly-expressed genes in PDA-cell population compared to Hep. (d) 
Disease pathway analysis of highly expressed genes in PDA-cell population compared 
to Hep by KEGG pathway online software tool. 
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1.2. Isolation and analysis of GFP expressing insulin-producing cells in liver 
(PDA-cell) using MIP-GFP mice. 
 
        
 
Figure 2. At day 7 of Ad-PDA injection into MIP-GFP mouse, liver cells were 
analyzed by flow cytometry and purified by GFP expression level. (a) Sample labeling 
and insulin transcriptional levels by qRT-PCR from each sample. Controls were 
sampled from primary hepatocyte (negative control) and pancreatic islet  (positive 
control) of untreated MIP-GFP mice. cDNA samples were pooled from 3 mice in each 
group. (b) Heatmap of pancreatic islet and hepatocyte markers expressed in Hep, 
PDA-cell and Islet (c) A diagram of different primer designs: CDS primers (in red) 
detecting both exogenous and endogenous gene expressions, and 3’ UTR primers (in 
green) amplifying only endogenous sequence. (d) mRNA expression of pancreatic 
markers highlighted in red [Fig. 1(b)] by qRT-PCR in Hep, PDA-cell and Islet 
samples. 
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1.3. Microarray based filtering algorithm to choose candidate genes in 
combination to PDA and candidate gene validation. 
                       
Figure 3. (a,b) Microarray gene scatter plots displaying islet-enriched genes by 2-fold 
cut-off from (a) PDA-cell vs. Islet. Set “A”, circled in red, denotes 4108 islet-enriched 
genes. (b) Hep vs. Islet. Set “B”, circled in red, denotes 3472 islet-enriched genes. (c) 
A Venn diagram of 2478 intersecting genes between set A and B from Figure 2a and 
2b, respectively. (d) A schematic diagram of filtering algorithm and candidate 
numbers at each step. (e, f) A heatmap of final candidate gene list and its qRT-PCR 
validation by 7 random genes labeled with °. (g) A map of pGL2-RIP II-251 used for 
in vitro insulin promoter assay. (h) Luciferase assay of pGL2/RIPII-251 by Ad-PDA 
with Ad-Isl1α, Ad-Isl1β or Ad-Elf3 and their protein expression levels by western blot. 
Isl1α and β were detected simultaneously on the same blot, using the same Isl1 
antibody (DSHB, #AB528315), which detects both Isl1α and β. Three independent 
experiments were performed. (i) Expression levels by qRT-PCR in luciferase assay of 
pGL2/RIPII-251 by pAd-PDA with pAd-Isl1α, pAd-Isl1β or pAd-Elf3. Exogenous 
primers (CDS) are used for detecting Pdx1, Neurod1, Mafa and Elf3. Data were 
analyzed by one-way ANOVA with Tukey-Kramer HSD test, *p < 0.05, ** p < 0.01, 
*** p < 0.001. 
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1.4. Bioluminescence screening image of combinatorial effects of Isl1β  and 
PDA using MIP-Luc-VU. 
 
           
 
Figure 4. (a) A schematic diagram of non-invasive bioluminescence imaging 
screening strategy. (b) Representative hepatic bioluminescence imaging at day 0, 3, 7, 
10 and 14 after injection with either Ad-PDA+GFP or Ad-PDA+Isl1β into MIP-Luc-
VU mice. Bioluminescence from lower-left quadrant of the animal signifies pancreatic 
signal; bioluminescence from upper abdomen signifies hepatic signal. Pancreatic 
signals are constantly emitted from endogenous β cells, thereby serve as background 
signal. Units were recorded in photons/sec/cm2/steradian within the range of 2.5x104 - 
2.5x105. (c) Average radiance was measured by number of photons emitted from 
hepatic region at day 3, 7, and 10 and from pancreatic region at day 0 and 14 per 
second per area of mouse abdominal surface in centimeter. (Ad-PDA+GFP, n=5; Ad-
PDA+Isl1β, n=5). Experiments were repeated at least three times independently. Data 
were analyzed by two-way ANOVA with Tukey-Kramer’s HSD test, *p < 0.05, ** p 
< 0.01, *** p < 0.001. 
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1.5. PDA+Isl1β  adenoviral treatment increased insulin production and 
secretion at day 7 in MIP-GFP mice.  
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Figure 5. (a-e) Representative figures of liver section by immunohistochemistry at 
day 7 of adenoviral injection with either Ad-PDA+LacZ or Ad-PDA+Isl1β. GFP 
signals signify insulin transcription. Merged figures include DAPI staining. Scale bar 
is 100µm. (a) Ad-PDA+LacZ infected liver sections stained with Pdx1, NeuroD and 
MafA antibody, which were visualized either in red or purple signals. (b) Ad-
PDA+Isl1β infected liver sections stained with Pdx1, NeuroD, MafA and Isl1 
antibody and visualized either in red or purple signals. Liver sections at day 7 of 
adenoviral treatment were stained with (c) Isl1 (d) Insulin or (e) Glucagon antibody. 
Pancreatic islet was used as positive control. 
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1.6. PDA+Isl1β  adenoviral treatment increased insulin production and 
secretion at day 7 in MIP-GFP mice     
                          
Figure 6. (a, b) Whole liver RNA was prepared from the same experimental mice set 
from Figure 5. Primer sequences are summarized in Table 1. (a) mRNA levels of 
Pdx1, Neurod1 and Mafa and Isl1β at day 7 by qRT-PCR. CDS primers [Fig. 2(c)] 
were used to detect PDA, which combine both adenovirus gene induction and 
endogenous expression level. Isl1β primer amplifies both α and β form, which denotes 
Isl1β in Ad-PDA+Islβ treated liver and Isl1α in islet. (b) mRNA levels of Ins1 and 
Ins2. (c, d) Samples were isolated from 6 mice per group. (c) Quantification of GFP 
expressing population by FACS. Data were analyzed by Student t-test, *p < 0.05. (d) 
mRNA level of Ins1 and Ins2 in GFP expressing cells by qRT-PCR. Data were 
analyzed by one-way ANOVA with Tukey-Kramer’s HSD test, *p < 0.05. (e, f) 
Insulin contents at day 7 of adenovirus treated mice from (e) liver or (f) serum. Data 
were obtained from 3 mice from each group and analyzed using one-way ANOVA 
followed by the Tukey-Kramer’s HSD test, *p < 0.05, ** p < 0.01. (g,h) MIP-GFP 
mice treated with either Ad-PDA+LacZ or Ad-PDA + Isl1β were measured for (g) Fed 
blood glucose levels at free fed status from tail snip, before (day 0) and after (day 7) 
of adenoviral treatment. (h) Body weight at day 0, 3 and 7 of adenoviral treatment. 
Data were analyzed by two-way ANOVA with Tukey-Kramer’s HSD test, * p <0.05, 
*** p<0.001 
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1.7. Adenoviral gene transfer of PDA+Isl1β  increased β  cell related genes in 
liver at day 7. 
 
 
 
Figure 7. Whole liver RNA was extracted from the same experimental mice used in 
Figure 4a-c. (a) mRNA levels of β cell markers: Pdx1, Neurod1, Mafa, Pax6 and 
Ucn3; α cell marker: Gcg. Endogenous Pdx1, Neurod1 and Mafa were detected using 
special primers which amplify 3’ untranslated region [Fig.2(c)]. (b) mRNA levels of β 
cell functional genes: Kir6.2, Pc2, Sur1 and Glut2. (c) mRNA levels of liver markers: 
Alb, Afp, and Hnf4a. LacZ indicates Ad-LacZ injected liver (negative control) of MIP-
GFP and pancreatic islets (positive control) were isolated from adenovirus untreated 
MIP-GFP mice. Primer sequences are summarized in Table 1. All data (each group, 
n=3) were analyzed by one-way ANOVA followed by Tukey-Kramer’s HSD test, *p 
< 0.05, ** p < 0.01, *** p < 0.001, n.s. non significant. 
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1.8. Streptozotocin induced diabetic mice improved glycemic control and 
response after treating with Ad-PDA+Isl1β . 
 
        
 
Figure 8. Streptozotocin (STZ; 200mg/kg) induced diabetic ICR mice were treated 
with adenovirus as follows: Ad-PDA+LacZ (n=5), Ad-PDA+Isl1β (n=5). Virus titer 
was reduced to one third of usual dosage (8.5x108 IFU). Experiments were repeated at 
least three times independently. Data analyzed by two-way ANOVA followed by 
Tukey-Kramer’s HSD test, *p < 0.05, ** p < 0.01, *** p < 0.001. (a) Fasting plasma 
glucose levels were measured once a week for 4 weeks. Day 0 is determined as the 
day of adenoviral injection. (b) Area under the curve of fasting glucose level in Figure 
a. Data were analyzed by one-way ANOVA followed by Tukey-Kramer’s HSD test, 
*p < 0.05. (c) Residual insulin contents from STZ induced mice pancreas at day 28 of 
adenoviral treatment with Ad-PDA+LacZ or Ad-PDA+Isl1β. Wt represents pancreas 
from non-STZ induced mice without adenovirus treatment. (Ad-PDA+GFP, n=5; Ad-
PDA+Isl1β, n=5; Wt, n=5). (d) Intraperitoneal glucose tolerance test (IPGTT) at day 7 
of adenovirus injection. (e) Area under curve of IPGTT in Figure d. Data were 
analyzed by one-way ANOVA followed by Tukey-Kramer’s HSD test, *p < 0.05. (f) 
In vivo glucose stimulated insulin secretion assay at day 7 of adenovirus injection. 
Plasma was collected at 0 and 30 minutes of glucose challenge. Data were analyzed 
by one-way ANOVA followed by Tukey-Kramer’s HSD test. 
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Chapter 6:  Tables 
 
1.1. The list of primer and their sequences used in this study 
Gene symbol Forward primer sequences Reverse primer sequences 
mIns1 gccctctgggagcccaaa agagagcctctaccagg 
mIns2 gcttcttctacacacccatgtc agcactgatctacaatgccac 
mPdx1 (CDS) ttcccgaatggaaccgagc gtaggcagtacgggtcctct 
mNeurod1 (CDS) acagacgctctgcaaaggttt ggactggtaggagtagggatg 
mMafa (CDS) cactggccatcgagtacgtca cttcacctcgaacttcatcaggtc 
mIsl1α (CDS) tcatccgagtgtggtttcaa ccatcatgtctctccggact 
mIsl1β (CDS) gaaggagcaactagtggagatgac agttttgtcgttgggttgct 
mEndogenousPdx1 gcgtcgcacaagaagaaaat tttcagaagctcagggctgt 
mEndogenousNeurod1 caaagccacggatcaatctt cccgggaatagtgaaactga 
mEndogenousMafa gaggaacagaaggaggaggag agtttcctgctgtcaactctgg 
mEndogenousIsl1 agcatcctctctgtgggcta cacgtacagctttcgtccaa 
mNkx2.2 atgtcgctgaccaacacaaa tcaccggacaatgacaagga 
mPax6 caggttgcgaagaactctgttt gcagatgcaaaagtccaggtg 
mGlut2 aaggatctgctcacatagtcact ttgcagccaacattgctttga 
mPC2 aatgacccctacccataccc gaggaggcttcgatgatgtc 
mSUR1 ctggtcctcagcagcacat ggaactcttgggacgagaca 
mKir6.2 gtaggggacctccgaaagag tggagtcgatgacgtggtag 
mUcn3 ttgcttctcggcttacctgt tgtgcacgtcacagagatga 
mGcg agggacctttaccagtgatgt aatggcgacttcttctgggaa 
mG6pc2 aggatgatgaagtgaacaca agaaggggctagcagatga 
mElf3 ttgaccctgaacaaccaaca gctctcttggaaggacatgc 
mGp2 ttgctgaccaactgctatgc ctttaaggccaggtgctcag 
mPtprtn ggctcctcctcagtccttct gccaaagacaggttctgctc 
mReg1 gctgaagaagacctgccatc gacgattccttttgggatca 
mAlb aattggcaacagacctgacc cctcaacaaaatcagcagca 
mAfp tcacatccacgaggagtgttgc ccttcaggtttgacgccattc 
mHnf4α ggtcaagctacgaggacagc atgtacttggcccactcgac 
mHprt ttgttgttggatatgcccttgacta aggcagatggccacaggacta 
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1.2. The list of antibodies used in this study  
Peptide/ 
Protein 
target 
Antigen 
sequence 
(if known) 
Name of Antibody 
Manufacturer, catalog 
#, and/or name of 
individual providing 
the antibody 
Species 
raised in; 
monoclonal 
or polyclonal 
Dilution 
used 
RRID 
(required 
in revised 
MSs) 
Isl1 
C terminal of rat 
islet-1 (aa 178-
349) 
Islet-1 DSHB, 40.2D6 
Mouse; 
monoclonal 
1 ; 500 AB52831
5 
Pdx1 
c-terminus of 
mouse PDX-1 Rabbit Anti-PDX-1 Cehmicon, Ab3243 
Rabbit; 
polyclonal 
1 ; 500 
AB77717
8 
NeuroD 
N-terminus of 
Neuro D of 
mouse Neuro D (N-19) Santa Cruz, sc-1084 
Goat; 
polyclonal 
1 ; 500 AB22824
74 
MafA 
near the C-
terminus MafA Antibody BL1069 Bethyl, A300-611A 
Rabbit; 
monoclonal 
1 ; 100 
AB12794
86 
Elf3  
Human/Mouse ELF3 
Antibody R&D systems, AF5787 
Goat; 
polyclonal 1 ; 500 
AB22781
32 
β-actin  
Anti-β-Actin pAb-HRP-
DirecT MBL, PM053-7 
Rabbit; 
polyclonal 1; 5000 
AB10697
035 
Insulin  
Anti-Insulin antibody 
ab7842 
Abcam, Ab7842 
Guinea pig; 
polyclonal 
1 ; 500 
AB30613
0 
Glucagon 
HSQGTFTSDY
SKYLDSRRAQ
DFVQWLMNT 
(M182) Anti-Glucagon, 
PolAb Takara, M182 polyclonal 1 ; 500 
AB26196
27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33 
Chapter 7: Summary and Conclusion 
 
In summary, I propose Isl1β as an essential insulin-producing factor, which 
facilitates Pdx1, Neuord1 and Mafa combination by increasing insulin production and 
glucose responsiveness through upregulating β cell related genes.  Thus, these findings 
provide a novel insight into the function of Isl1β as therapeutic candidate for gene therapy 
through in vivo β cell generation to compensate the compromised β cell function in 
diabetes. 
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